Jeffrey J Adamovicz

List of Publications by Year
in descending order

26	1,025	471509 17	552781 26
papers	citations	h-index	g-index

27	27	27	703
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Binding Sites of Anti-Lcr V Monoclonal Antibodies Are More Critical than the Avidities and Affinities for Passive Protection against Yersinia pestis Infection in a Bubonic Plague Model. Antibodies, 2020, 9, 37.	2.5	5
2	Toxoplasma gondii seropositivity and the associated risk factors in sheep and pregnant women in El-Minya Governorate, Egypt. Veterinary World, 2020, 13, 54-60.	1.7	15
3	Prevalence of and risk factors associated with ovine progressive pneumonia in Wyoming sheep flocks. Journal of the American Veterinary Medical Association, 2015, 247, 932-937.	0.5	8
4	Evaluation of Imipenem for Prophylaxis and Therapy of Yersinia pestis Delivered by Aerosol in a Mouse Model of Pneumonic Plague. Antimicrobial Agents and Chemotherapy, 2014, 58, 3276-3284.	3.2	11
5	VALIDATION OF QUANTITATIVE ELISAs FOR MEASURING ANTI-YERSINIA PESTISF1 AND V ANTIBODY CONCENTRATIONS IN NONHUMAN PRIMATE SERA. Journal of Immunoassay and Immunochemistry, 2012, 33, 91-113.	1.1	1
6	Identification ofIn Vivo-Induced Conserved Sequences fromYersinia pestisDuring Experimental Plague Infection in the Rabbit. Vector-Borne and Zoonotic Diseases, 2010, 10, 749-756.	1.5	7
7	Quantitative anti-F1 and anti-V IgG ELISAs as serological correlates of protection against plague in female Swiss Webster mice. Vaccine, 2010, 28, 934-939.	3.8	8
8	TNFÎ± and IFNÎ³ contribute to F1/LcrV-targeted immune defense in mouse models of fully virulent pneumonic plague. Vaccine, 2010, 29, 357-362.	3.8	47
9	Protection in mice passively immunized with serum from cynomolgus macaques and humans vaccinated with recombinant plague vaccine (rF1V). Vaccine, 2010, 28, 7748-7756.	3.8	28
10	CpG oligodeoxynucleotides augment the murine immune response to the Yersinia pestis F1-V vaccine in bubonic and pneumonic models of plague. Vaccine, 2009, 27, 2220-2229.	3.8	30
11	Exogenous Yersinia pestis quorum sensing molecules N-octanoyl-homoserine lactone and N-(3-oxooctanoyl)-homoserine lactone regulate the LcrV virulence factor. Microbial Pathogenesis, 2009, 46, 283-287.	2.9	15
12	Application of carbohydrate microarray technology for the detection of Burkholderia pseudomallei, Bacillus anthracis and Francisella tularensis antibodies. Carbohydrate Research, 2008, 343, 2783-2788.	2.3	29
13	Evaluation of quantitative anti-F1 IgG and anti-V IgG ELISAs for use as an in vitro-based potency assay of plague vaccine in mice. Biologicals, 2008, 36, 287-295.	1.4	5
14	Antibodies and cytokines independently protect against pneumonic plague. Vaccine, 2008, 26, 6901-6907.	3.8	44
15	Modified Caspase-3 Assay Indicates Correlation of Caspase-3 Activity with Immunity of Nonhuman Primates to Yersinia pestis Infection. Vaccine Journal, 2008, 15, 1134-1137.	3.1	20
16	Effective Plague Vaccination via Oral Delivery of Plant Cells Expressing F1-V Antigens in Chloroplasts. Infection and Immunity, 2008, 76, 3640-3650.	2.2	120
17	Development of In Vitro Correlate Assays of Immunity to Infection with Yersinia pestis. Vaccine Journal, 2007, 14, 605-616.	3.1	65
18	Purification and protective efficacy of monomeric and modified Yersinia pestis capsular F1-V antigen fusion proteins for vaccination against plague. Protein Expression and Purification, 2007, 53, 63-79.	1.3	26

#	Article	IF	Citations
19	Multiple asparagine deamidation of Bacillus anthracis protective antigen causes charge isoforms whose complexity correlates with reduced biological activity. Proteins: Structure, Function and Bioinformatics, 2007, 68, 458-479.	2.6	22
20	Intranasal Protollinâ„¢/F1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection. Vaccine, 2006, 24, 1625-1632.	3.8	50
21	Comparative vaccine efficacy of different isoforms of recombinant protective antigen against Bacillus anthracis spore challenge in rabbits. Vaccine, 2006, 24, 3469-3476.	3.8	24
22	Design and Testing for a Nontagged F1-V Fusion Protein as Vaccine Antigen against Bubonic and Pneumonic Plague. Biotechnology Progress, 2005, 21, 1490-1510.	2.6	88
23	Yersinia pestis V Protein Epitopes Recognized by CD4 T Cells. Infection and Immunity, 2005, 73, 2197-2204.	2.2	27
24	Protection against Aerosolized Yersinia pestis Challenge following Homologous and Heterologous Prime-Boost with Recombinant Plague Antigens. Infection and Immunity, 2005, 73, 5256-5261.	2.2	47
25	Flea-Borne Transmission Model To Evaluate Vaccine Efficacy against Naturally Acquired Bubonic Plague. Infection and Immunity, 2004, 72, 2052-2056.	2.2	33
26	Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine, 1998, 16, 1131-1137.	3.8	249